Physician profile
Feng Chen
NPI 1184607749
$3,814.39
in general payments reported to CMS, 2019-2025
22 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,513 · 2020: $517 · 2021: $390 · 2022: $184 · 2023: $792 · 2024: $205 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,200.96 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $501.26 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $300.64 | 2019-2023 | Mounjaro, Jardiance |
| Pfizer INC. | $271.63 | 2019-2023 | |
| Amarin Pharma, INC. | $264.11 | 2019-2022 | |
| Glaxosmithkline, LLC. | $210.60 | 2019-2023 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $206.52 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $172.63 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.61 | 2019-2021 | |
| Amgen INC. | $144.50 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $64.67 | 2019-2021 | |
| Abbott Laboratories | $54.38 | 2023-2025 | Freestyle Libre |
| Janssen Pharmaceuticals, INC | $52.75 | 2019-2021 | |
| Exact Sciences Corporation | $50.37 | 2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $30.32 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $28.88 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $25.46 | 2019-2020 | |
| Dexcom, INC. | $21.37 | 2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $19.27 | 2021 | |
| Esperion Therapeutics, INC. | $17.80 | 2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $13.48 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Feng Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.